Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer Jeito Capital co-leads oversubscribed EUR 50 million Series C financing with Brandon Capital CatalYm is developing a new class of anti-cancer immunotherapies, which have already demonstrated initial promising clinical results in advanced-stage solid tumor patients […]